Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Respiratory Syncytial Virus (RSV) Therapeutics Market
The Respiratory Syncytial Virus (RSV) Therapeutics market was valued at USD 609 million in 2023, and the market is now projected to grow to USD 4003 million by 2032, exhibiting a CAGR of 30.9% during the forecast period of 2024-2032.
The sudden development of the pandemic has disturbed the pharma companies with respect to the day-to-day exercises and moved the focus on minimizing the impacts caused. In July 2020, the agents of Sanofi commented that the flare-up of COVID-19 had disturbed the clinical trials for the consider of nirsevimab. The challenges incorporate understanding enrolment and quiet maintenance amid the trials. The company too expressed that the COVID-19 flare-up seem to affect the RSV contamination season, making it troublesome to assess the drug's adequacy amid clinical trials and impacting the Respiratory Syncytial Virus (RSV) Therapeutics market growth.
Contributing within the improvement of a novel component to improve adequacy and decrease the drug's fetched is one of the key patterns displayed by the market players. Nirsevimab, which is slated to dispatch in 2023, is assessed to be estimated at USD 600 compared to a whopping USD 6,000 cost tag of palivizumab. A collaborative approach towards finding the treatment and preventative therapeutics for RSV infection is among the transcendent patterns experienced within the market. In expansion, key players are centring on organizations to extend their chances for disclosure of the treatment and capture the neglected request from the contaminated populace.
The utilize of monoclonal antibodies in newborn children to cause inactive immunization is one of the key approaches being sought after by the pharmaceutical companies in their battle against RSV. The pipeline items offer noteworthy benefits over Synagis and the other approach of inoculating pregnant moms to supply detached immunization to newborn children. Components, such as novel instruments, lower cost, and security for the complete season through one infusion and prompt security against the disease are evaluated to augment market development.
Comprehensive Analysis of Respiratory Syncytial Virus (RSV) Therapeutics Market
On the brief analysis of drug type, the market for Respiratory Syncytial Virus (RSV) Therapeutics is being bifurcated into treatment and prophylaxis, among these two the prophylaxis raises up as the dominant part of the drug type segmentation. Hospital pharmacy, online pharmacy and retail pharmacy are the three branches of the end-user analysis, amongst the three the fragment hospital is governed to the dominant part of end-user analyzation.
The North America respiratory syncytial virus (RSV) therapeutics market share stood at USD 396.0 million in 2019 and will colossally develop all through the figure period. The development is inferable to the higher predominance of RSV disease as well as bigger get to for the treatment of the disease. Concurring to the Centre for Disease Control and Anticipation (CDC), RSV contamination leads to nearly 2.1 million outpatient visits among children more youthful than five a long time of age yearly within the U.S. alone.
The market for the Respiratory Syncytial Virus (RSV) Therapeutics is majorly comprised of the prominent players that are operating dedicatedly in the market, proving their existence and profitable revenues with the extensive research and innovative practices and product development. The market enlisted are as: AstraZeneca (U.K), Bausch Health Companies Inc. (U.S), AbbVie (U.S), Johnson and Johnson Services Inc. (U.S), Sanofi (France), Merck & Co., Inc. (U.S), Celltrion Inc. (South Korea), mAbxience (Spain) and Enanta Pharmaceuticals, Inc (U.S).
These players accounted for an overwhelming share in 2019 and are likely to hold their driving position amid the estimate period. In any case, the need of solid passage obstructions is anticipated to lead to an expanding number of residential players entering the worldwide advertise. The developing number of companies entering the drone industry is anticipated to lead to a profoundly divided market.
In the month of June 2021, the company by name AstraZeneca declared that they have gotten positive security, and tolerability comes about for their long-acting counter acting agent medicate of nirsevimab created for the treatment of newborn children enduring from high chance of respiratory syncytial infection (RSV) amid the Variety Stage II/III trial.
SEGMENTATION TABLE
ATTRIBUTE DETAILS
Study Period 2016-2027
Base Year 2019
Forecast Period 2020-2027
Historical Period 2016-2018
Unit Value (USD million)
Segmentation By Drug Class
Prophylaxis
Palivizumab
Nirsevimab
MK-1654
Other Prophylaxis
Treatment
Ribavirin
JNJ 53718678
Enanta EDP-938
ASCENIV
By End User
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Geography
North America (U.S. and Canada)
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
Latin America (Brazil, Mexico, and Rest of Latin America)
Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Potential Vaccine Candidates and Potential Impact of Approvals on the Treatment Market
- 4.2. Trends: Changing Landscape Treatment & Prophylaxis, Unmet Needs, etc.
- 4.3. Total Number of Patients Receiving Palivizumab, Key Countries/ Region
- 4.4. Potential Vaccine Candidates and Potential Impact of Approvals on the Treatment Market
- 4.5. Trends: Changing Landscape Treatment & Prophylaxis, Unmet Needs, etc.
- 4.6. Total Number of Patients Receiving Palivizumab, Key Countries/ Region
- 4.7. Impact of Covid-19 on the Market
- 5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Drug Class
- 5.2.1. Prophylaxis
- 5.2.1.1. Palivizumab
- 5.2.1.2. Nirsevimab
- 5.2.1.3. MK-1654
- 5.2.1.4. Other Prophylaxis (Vaccines)
- 5.2.2. Treatment
- 5.2.2.1. Ribavirin
- 5.2.2.2. All New Treatment
- 5.2.2.2.1. JNJ 53718678
- 5.2.2.2.2. Enanta EDP-938
- 5.2.2.2.3. ASCENIV
- 5.3. Market Analysis, Insights and Forecast – By End User
- 5.3.1. Hospital Pharmacies
- 5.3.2. Retail Pharmacies
- 5.3.3. Online Pharmacies
- 5.4. Market Analysis, Insights and Forecast – By Country
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
- 6. North America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis – By Drug Class
- 6.2.1. Prophylaxis
- 6.2.1.1. Palivizumab
- 6.2.1.2. Nirsevimab
- 6.2.1.3. MK-1654
- 6.2.1.4. Other Prophylaxis (Vaccines)
- 6.2.2. Treatment
- 6.2.2.1. Ribavirin
- 6.2.2.2. All New Treatment
- 6.2.2.2.1. JNJ 53718678
- 6.2.2.2.2. Enanta EDP-938
- 6.2.2.2.3. ASCENIV
- 6.3. Market Analysis – By End User
- 6.3.1. Hospital Pharmacies
- 6.3.2. Retail Pharmacies
- 6.3.3. Online Pharmacies
- 6.4. Market Analysis – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
- 7. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis – By Drug Class
- 7.2.1. Prophylaxis
- 7.2.1.1. Palivizumab
- 7.2.1.2. Nirsevimab
- 7.2.1.3. MK-1654
- 7.2.1.4. Other Prophylaxis (Vaccines)
- 7.2.2. Treatment
- 7.2.2.1. Ribavirin
- 7.2.2.2. All New Treatment
- 7.2.2.2.1. JNJ 53718678
- 7.2.2.2.2. Enanta EDP-938
- 7.2.2.2.3. ASCENIV
- 7.3. Market Analysis – By End User
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail Pharmacies
- 7.3.3. Online Pharmacies
- 7.4. Market Analysis – By Country
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Italy
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
- 8. Asia pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis – By Drug Class
- 8.2.1. Prophylaxis
- 8.2.1.1. Palivizumab
- 8.2.1.2. Nirsevimab
- 8.2.1.3. MK-1654
- 8.2.1.4. Other Prophylaxis (Vaccines)
- 8.2.2. Treatment
- 8.2.2.1. Ribavirin
- 8.2.2.2. All New Treatment
- 8.2.2.2.1. JNJ 53718678
- 8.2.2.2.2. Enanta EDP-938
- 8.2.2.2.3. ASCENIV
- 8.3. Market Analysis – By End User
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail Pharmacies
- 8.3.3. Online Pharmacies
- 8.4. Market Analysis – By Country
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
- 9. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis – By Drug Class
- 9.2.1. Prophylaxis
- 9.2.1.1. Palivizumab
- 9.2.1.2. Nirsevimab
- 9.2.1.3. MK-1654
- 9.2.1.4. Other Prophylaxis (Vaccines)
- 9.2.2. Treatment
- 9.2.2.1. Ribavirin
- 9.2.2.2. All New Treatment
- 9.2.2.2.1. JNJ 53718678
- 9.2.2.2.2. Enanta EDP-938
- 9.2.2.2.3. ASCENIV
- 9.3. Market Analysis – By End User
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail Pharmacies
- 9.3.3. Online Pharmacies
- 9.4. Market Analysis – By Country
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
- 10. Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 10.1. Key Findings / Summary
- 10.2. Market Analysis – By Drug Class
- 10.2.1. Prophylaxis
- 10.2.1.1. Palivizumab
- 10.2.1.2. Nirsevimab
- 10.2.1.3. MK-1654
- 10.2.1.4. Other Prophylaxis (Vaccines)
- 10.2.2. Treatment
- 10.2.2.1. Ribavirin
- 10.2.2.2. All New Treatment
- 10.2.2.2.1. JNJ 53718678
- 10.2.2.2.2. Enanta EDP-938
- 10.2.2.2.3. ASCENIV
- 10.3. Market Analysis – By End User
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail Pharmacies
- 10.3.3. Online Pharmacies
- 10.4. Market Analysis – By Country
- 10.4.1. GCC Countries
- 10.4.2. South Africa
- 10.4.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2019)
- 11.3. Competition Dashboard
- 11.4. Comparative Analysis – Major Players
- 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 11.5.1. AstraZeneca
- 11.5.1.1. Overview,
- 11.5.1.2. Products & services,
- 11.5.1.3. SWOT analysis,
- 11.5.1.4. Recent developments,
- 11.5.1.5. strategies,
- 11.5.1.6. financials (based on availability)
- 11.5.2. Bausch Health Companies Inc
- 11.5.2.1. Overview,
- 11.5.2.2. Products & services,
- 11.5.2.3. SWOT analysis,
- 11.5.2.4. Recent developments,
- 11.5.2.5. strategies,
- 11.5.2.6. financials (based on availability)
- 11.5.3. AbbVie
- 11.5.3.1. Overview,
- 11.5.3.2. Products & services,
- 11.5.3.3. SWOT analysis,
- 11.5.3.4. Recent developments,
- 11.5.3.5. strategies,
- 11.5.3.6. financials (based on availability)
- 11.5.4. Johnson & Johnson Services, Inc.
- 11.5.4.1. Overview,
- 11.5.4.2. Products & services,
- 11.5.4.3. SWOT analysis,
- 11.5.4.4. Recent developments,
- 11.5.4.5. strategies,
- 11.5.4.6. financials (based on availability)
- 11.5.5. Sanofi
- 11.5.5.1. Overview,
- 11.5.5.2. Products & services,
- 11.5.5.3. SWOT analysis,
- 11.5.5.4. Recent developments,
- 11.5.5.5. strategies,
- 11.5.5.6. financials (based on availability)
- 11.5.6. Merck & Co., Inc
- 11.5.6.1. Overview,
- 11.5.6.2. Products & services,
- 11.5.6.3. SWOT analysis,
- 11.5.6.4. Recent developments,
- 11.5.6.5. strategies,
- 11.5.6.6. financials (based on availability)
- 11.5.7. Celltrion Inc.
- 11.5.7.1. Overview,
- 11.5.7.2. Products & services,
- 11.5.7.3. SWOT analysis,
- 11.5.7.4. Recent developments,
- 11.5.7.5. strategies,
- 11.5.7.6. financials (based on availability)
- 11.5.8. mAbxience
- 11.5.8.1. Overview,
- 11.5.8.2. Products & services,
- 11.5.8.3. SWOT analysis,
- 11.5.8.4. Recent developments,
- 11.5.8.5. strategies,
- 11.5.8.6. financials (based on availability)
- 11.5.9. Enanta Pharmaceuticals, Inc
- 11.5.9.1. Overview,
- 11.5.9.2. Products & services,
- 11.5.9.3. SWOT analysis,
- 11.5.9.4. Recent developments,
- 11.5.9.5. strategies,
- 11.5.9.6. financials (based on availability)
- 12. Strategic Recommendations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook